AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2921600
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride 50 mg/day
Trial: 2921600
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride 100 mg/day
Trial: 25446610
Drug: RT with
RxNorm normalized name: NuCort with Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT with capecitabine (1200 mg/m²/d Monday‐Friday) plus irinotecan (50 mg/m²/wk × 4)
Trial: 25446610
Drug: RT with
RxNorm normalized name: NuCort with Aloe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT with capecitabine (1650 mg/m²/d Monday‐Friday) plus oxaliplatin (50 mg/m²/wk × 5)
Trial: 23691062
Drug: Anti-tuberculosis therapy
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis therapy (ATT) with corticosteroids for IRIS treatment
Trial: 17412546
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses compared to 0.01mmol/kg
Trial: 14769684
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg)
Trial: 11124753
Drug: Lithium-tagged yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium-tagged yogurt (500 mL) for 6 weeks
Trial: 11124753
Drug: Lithium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium supplement (250 micromol/d) for 13 days
Trial: 11124753
Drug: Half the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half the dose (125 micromol lithium/d) taken on each of 2 days
Trial: 24501164
Drug: EMLA® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® cream
Trial: 9188873
Drug: EMLA® patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® patch
Trial: 8453559
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant interferon alfa‐2a and IL‐2 at a dose of 7.5 million units (MU)/m2 of interferon alfa‐2a and 1.5 MU/m2 of IL‐2, administered three and five times weekly for 4 weeks
Trial: 2943106
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (150 mg trimestrially)
Trial: 2943106
Drug: Ethinyl-oestradiol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl-oestradiol (1 mg daily for 5 days)
Trial: 29337026
Drug: rhGH 4
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 4 mg group
Trial: 29337026
Drug: rhGH 8
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 8 mg group
Trial: 22353915
Drug: Education group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education group (Group II) - guardians received a pamphlet about how to help a child cooperate with the dentist during dental treatment.
Trial: 20198451
Drug: 15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg total body weight (TBW) of IV crystalloid solution (Group A)
Trial: 20198451
Drug: 40 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml/kg total body weight (TBW) of IV crystalloid solution (Group B)
Trial: 18668692
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of dexamethasone (1 mg/kg)
Trial: 18668692
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of dexamethasone (0.15 mg/kg for 4 days)
Trial: 18668692
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of dexamethasone
Trial: 18668692
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of dexamethasone
Trial: 10614835
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (initial dose of 2.0 g followed by a constant infusion at 20 mg/min)
Trial: 7627244
Drug: Orlistat 30
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 30 mg/day
Trial: 7627244
Drug: Orlistat 180
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 180 mg/day
Trial: 7627244
Drug: Orlistat 360
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 360 mg/day
Trial: 1512604
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (50 mg daily) and dipyridamole (400 mg daily)
Trial: 6390998
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin in combination with dihydroergotamine
Trial: 30328246
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 100 mg/day for 8 weeks
Trial: 22278874
Drug: Antistick phospholipid
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antistick phospholipid solution (Electro Lube)
Trial: 22278874
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antistick solution)
Trial: 21084043
Drug: Contiflo ICON
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contiflo ICON 400 µg tablets
Trial: 21084043
Drug: Flomaxtra XL
RxNorm normalized name: XL-888
DrugBank: XL-888 (DB12981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flomaxtra XL 400 µg tablets
Trial: 15906662
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.7 mg/kg/d) plus rifampin (600 mg/d) for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Trial: 15906662
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.7 mg/kg/d) alone for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Trial: 10558970
Drug: Partially enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially enteric‐coated preparation of bovine immunoglobulins
Trial: 1846057
Drug: lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (10 to 40 mg)
Trial: 16785331
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 to 100 mg)
Trial: 6354602
Drug: Ciramadol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol (60 or 30 mg)
Trial: 28527421
Drug: Lofexidine HCl
RxNorm normalized name: lofexidine HCl
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lofexidine HCl 3.2mg daily in four divided doses
Trial: 24090266
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of ramelteon (melatonin agonist)
Trial: 19623858
Drug: Mean Lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean Lung Dose (MLD)
Trial: 15086698
Drug: Standard urticaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard urticaria therapies (corticosteroids, H2-antihistamines, H1-antihistamines, doxepin)
Trial: 7714461
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (2.5 or 10 mg daily for 6 weeks)
Trial: 27937064
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (Fp) delivered via MDPI 50, 100, 200, or 400 mcg twice daily for 12 weeks
Trial: 27937064
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (Fp) delivered via DPI 250 mcg
Trial: 24923372
Drug: Thiopentone sodium
RxNorm normalized name: Thiopentone sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone sodium (5 mg/kg)
Trial: 17131169
Drug: Solifenacin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (both doses)
Trial: 11603453
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (10 mg/kg) 4 hours preoperatively
Trial: 12520569
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no steroid administration)
Trial: 9847641
Drug: 0.5% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% tetracaine drops and intravenous fentanyl and propofol with continuous sedation (Group I)
Trial: 9847641
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine in the retrobulbar space and hypnotic doses of intravenous propofol (Group II)
Trial: 2634902
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg twice daily)
Trial: 712981
Drug: Megavitamin combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megavitamin combination
Trial: 25684006
Drug: Fentanyl group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl group (0.5% hyperbaric bupivacaine 0.2 mL + fentanyl 20 μg + 5% dextrose 1.4 mL)
Trial: 25684006
Drug: Sufentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil group (0.5% hyperbaric bupivacaine 0.2 mL + sufentanil 5 μg + 5% dextrose 1.7 mL)
Trial: 17931382
Drug: BNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP plasma levels low (< 100 pg mL(‐1))
Trial: 17931382
Drug: BNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP plasma levels intermediate (100-500 pg mL(‐1))
Trial: 17931382
Drug: BNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP plasma levels high (> 500 pg mL(‐1))
Trial: 15230644
Drug: Tegaserod 6mg
RxNorm normalized name: tegaserod 6 MG
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tegaserod 6mg twice daily
Trial: 9219678
Drug: Hyalgan (500-730
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyalgan (500-730 kDa molecular weight), three cycles of three intra-articular injections (once a week during 2 weeks) every 3 months
Trial: 8424294
Drug: Metoclopramide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (1 mg.kg‐1 i.v. preoperatively, followed by 1.5 mg.kg‐1 infusion over 9 h)
Trial: 29614243
Drug: HP/TAZ lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP/TAZ lotion (halobetasol propionate 0.01% plus tazarotene 0.045%)
Trial: 27037169
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 2% Carbocaine lidocaine gel with 1 mL 0.9% saline (group 1)
Trial: 27037169
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL 5% NaHCO3 solution (group 2)
Trial: 24997651
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g dose of tranexamic acid (Group 1)
Trial: 24997651
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg dose of tranexamic acid (Group 2)
Trial: 18211278
Drug: Assessment/attention comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment/attention comparison group with typical treatment available
Trial: 12949850
Drug: Risperidone 1
RxNorm normalized name: risperidone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1 to 3 mg/day
Trial: 10966692
Drug: Oral temazepam
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral temazepam (group B)
Trial: 10966692
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (group C)
Trial: 10966692
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam and fentanyl (group D)
Trial: 8990802
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of calcium/day for 4 weeks
Trial: 30914044
Drug: Delayed antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotic prescription (DAP) for respiratory tract infections (RTIs)
Trial: 22782352
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 14 days
Trial: 20107799
Drug: Suramin plus
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin plus docetaxel 75 mg/m²
Trial: 20107799
Drug: Suramin plus
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin plus docetaxel 56 mg/m²
Trial: 20107799
Drug: Suramin plus
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin plus gemcitabine 1,250 mg/m²
Trial: 18485031
Drug: Suspension technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension technique
Trial: 18485031
Drug: No suspension
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No suspension technique
Trial: 12122554
Drug: SSM+ (semisolid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSM+ (semisolid meal with 2.5 g GG)
Trial: 7494721
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group program aimed at diminishing affective components of negative attitudes towards neuroleptics
Trial: 2089252
Drug: Low-dose calcitriol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcitriol (0.25 microgram b.i.d.) and 1 g of supplemental calcium therapy
Trial: 2089252
Drug: Ergocalciferol (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (50,000 units twice a week) and 1 g of supplemental calcium
Trial: 19321575
Drug: 5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/d seaweed (Alaria)
Trial: 16481636
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D supplementation (500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 twice daily for an average of 7.0 years)
Trial: 11382835
Drug: Vascupump treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascupump treatment (20 sessions of 45 minutes each)
Trial: 11382835
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with Vascupump and Pentoxillin (3 fl/per diem for 20 days)
Trial: 8058074
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg daily)
Trial: 26375689
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist liraglutide
Trial: 24660607
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions of puncturing acupuncture at various acupoints including Hegu (LI 4))
Trial: 16442211
Drug: Tamsulosin OCAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin OCAS 0.4 mg
Trial: 16442211
Drug: Alfuzosin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin XL 10 mg
Trial: 14709244
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) 400 mg bid plus interferon alpha‐2b (IFN‐alpha) 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induction arm)
Trial: 14709244
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) 400 mg bid plus interferon alpha‐2b (IFN‐alpha) 3 mU tiw (control arm)
Trial: 11112016
Drug: High-dose ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ATG (9 mg/kg body weight, single intravenous injection)
Trial: 11112016
Drug: High-dose ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ATG
Trial: 9420308
Drug: RT inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT inhibitors (Nevirapine and Zidovudine)
Trial: 2872811
Drug: Terazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1 to 40 mg, single daily doses)
Trial: 29387931
Drug: Single instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single instillation of THP (30 mg/50 mL) immediately after TURBT (Group A)
Trial: 25308780
Drug: i-gel size
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i-gel size 1
Trial: 23965882
Drug: MMF1 (mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF1 (mycophenolate mofetil after 2 weeks of conventional treatment)
Trial: 23965882
Drug: MMF2 (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF2 (combination therapy with non-steroidal anti-inflammatory drugs, prednisone, and MMF)
Trial: 16868226
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg subcutaneously every 4 weeks for 12 weeks)
Trial: 12182257
Drug: Cefditoren 200
RxNorm normalized name: cefditoren 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren 200 mg BID for 10 days
Trial: 12182257
Drug: Cefditoren 400
RxNorm normalized name: cefditoren 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren 400 mg BID for 10 days
Trial: 12182257
Drug: Cefuroxime 250
RxNorm normalized name: cefuroxime 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 250 mg BID for 10 days
Trial: 12182257
Drug: Cefadroxil 500
RxNorm normalized name: cefadroxil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 500 mg BID for 10 days
Trial: 12182257
Drug: Cefditoren 200
RxNorm normalized name: cefditoren 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren 200 mg vs Cefuroxime
Trial: 12182257
Drug: Cefditoren 200
RxNorm normalized name: cefditoren 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren 200 mg vs Cefadroxil
Trial: 12182257
Drug: Cefditoren 400
RxNorm normalized name: cefditoren 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren 400 mg vs Cefadroxil
Trial: 12182257
Drug: Cefditoren 400
RxNorm normalized name: cefditoren 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefditoren 400 mg
Trial: 10482825
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg daily for 5 months
Trial: 10482825
Drug: Fluconazole (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (continued treatment in phase 2)
Trial: 8738765
Drug: Once-daily aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily aminoglycoside dosing (ODA)
Trial: 25057140
Drug: Live Educational
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live Educational Music Therapy
Trial: 25057140
Drug: Recorded Educational
RxNorm normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recorded Educational Music Therapy
Trial: 25057140
Drug: Recreational Music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational Music Therapy
Trial: 25057140
Drug: Recreational Music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational Music Therapy without Education
Trial: 17219174
Drug: Intensified training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified training (IT) followed by a 7-day taper
Trial: 17219174
Drug: Normal training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal training (NT) followed by a 7-day taper
Trial: 20486868
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) for 6 months
Trial: 9590915
Drug: Intraligamentary technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamentary technique of anesthetic administration (ILA)
Trial: 8250678
Drug: Morning light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning light therapy (2500 lux for 1 hour for 1 week)
Trial: 8250678
Drug: Evening light
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening light therapy (2500 lux for 1 hour for 1 week)